POLITICO Playbook: Scoop: Manchin-Sinema split vexes the White House

So what’s the state of negotiations between the White House and JOE MANCHIN and KYRSTEN SINEMA?

The talks have been shrouded in mystery, but we have some fresh details we can share this morning.

More is known about Manchin than Sinema, and for a good reason: While Manchin has been willing to discuss his priorities in detail with his colleagues in the Senate, Sinema only negotiates with the White House.

“I’m not going to share with you or with Schumer or with Pelosi,” she told one Democratic senator recently. “I have already told the White House what I am willing to do and what I’m not willing to do. I’m not mysterious. It’s not that I can’t make up my mind. I communicated it to them in detail. They just don’t like what they’re hearing.”

Part of solving the Manchinema puzzle is that the 74-year-old former governor from a coal state and the 45-year-old former Green Party activist from Arizona are at odds on some major policies.

“Manchin and Sinema want very different things, both in terms of revenue and programs,” said a source close to Biden who spent the last few days talking to senior White House officials. “If you just took their currently presented red lines you wouldn’t have enough left to get this past progressives in the House and Senate. It wouldn’t raise enough money and it wouldn’t do enough big programs.”

The biggest obstacle Sinema has created, according to Democrats, is on prescription drug pricing reform.

The most robust version of this plan to allow Medicare to negotiate drug prices would bring in some $800 billion of revenue at the expense of the pharmaceutical industry. It’s one of the most popular policies on the Democrats’ menu of options and many party strategists believe Democrats owe their House majority to this issue.

But we’re told that Democrats would be lucky if they managed to convince Sinema to support a version of drug pricing reform that raises even $200 billion. That’s not enough to fund the expansion of Medicare benefits that Sen. BERNIE SANDERS (I-Vt.) wants or the expansion of the ACA that Speaker NANCY PELOSI wants.

Manchin is much more willing to support a bolder version of drug pricing reform. But he’s also insisting on including his own pet plan to tax prescription opioids — a tax vehemently opposed by Sinema’s allies at PhRMA and one that would dilute the Democrats’s prescription drug pricing plan. So far, the White House has not been able to convince Manchin to drop his opioid tax idea.

The two senators are similarly at odds over climate policy: Manchin opposes several Democratic ideas to price carbon pollution, while Sinema favors them.

And here’s where Manchin is really…